In the past decade, oncologists worldwide have seen unprecedented advances in drug
development and approvals but have also become increasingly cognizant of the rising costs …

In both pediatric and adult populations with type 1 diabetes (T1D), technologies such as
continuous subcutaneous insulin infusion (CSII), continuous glucose monitoring (CGM), or …

Objective: Global expenditure on medicines is increasing driven by a number of factors.
These include the launch of new premium-priced medicines for complex diseases including …

We report the novel clinical presentation of a primary brain neoplasm in a 30-year-old man
with a mass-like area in the anteromedial temporal lobe. Histopathological analysis …

Objectives Cost effectiveness analysis (CEA) has been increasingly used to inform cancer
treatment coverage policy making worldwide. The primary objective of this study was to …

There are a number of ongoing developments to improve the care of patients with diabetes
across countries given its growing burden. Recent developments include new oral …

Introduction Access to medicines is a shared goal across healthcare stakeholders. Since
health technology assessment (HTA) informs funding decisions, it shapes access to …

Rare cancers, defined as those with an annual incidence of fewer than six cases per
100,000 individuals, are associated with significant health inequalities. This study aimed to …

Objective This article reviews the assessment pathways that have been implemented
worldwide to facilitate access to drugs for patients with rare diseases. Methods The …

Objectives: The aim of this study was to characterize the reimbursement policy for orphan
drugs (ODs) in Central and Eastern European (CEE) countries in relation to the availability …